Multimodality Therapies for Localized Prostate Cancer.

Abstract

PURPOSE OF REVIEW:

Multimodality therapy including radical prostatectomy, radiation therapy, and hormone therapy are frequently deployed in the management of localized prostate cancer. We sought to perform a critical appraisal of the most contemporary literature focusing on the multimodality management of localized prostate cancer.

RECENT FINDINGS:

Men who are ideal candidates for multimodality therapy include those with unfavorable intermediate-risk disease, high-risk disease, and very high-risk disease. Enhancements in both systemic agents (including second-generation antiandrogens) as well as localized therapies (such as stereotactic body radiotherapy and brachytherapy) are refining the optimal balance between the use of systemic and local therapies for localized prostate cancer. Genomic predictors are emerging as critical tools for more precisely allocating treatment intensification with multimodality therapies as well as treatment de-intensification. Close collaboration among medical oncologists, surgeons, and radiation oncologists will be critical for coordinating evidence-based multimodality therapies when clearly indicated and for supporting shared decision-making in areas where the evidence is mixed.

• Authors: Luca F Valle, Tommy Jiang, Adam B Weiner, Robert E Reiter, Matthew B Rettig, John Shen, Albert J Chang, Nicholas G Nickols, Michael L Steinberg, Amar U Kishan
• Journal: Current oncology reports (Curr Oncol Rep) Vol. 25 Issue 3 Pg. 221-229 (03 2023) ISSN: 1534-6269 [Electronic] United States
• PMID: 36723856 (Publication Type: Journal Article, Review)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• Androgen Antagonists

Topics

• Male
• Humans
• Prostatic Neoplasms (therapy)
• Brachytherapy
• Combined Modality Therapy
• Prostatectomy
• Androgen Antagonists